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Abstract 
Microbiological quality control of probiotic products such as Imunele, Dannon, Pomogayka showed that they contain living 
cultures of the Lactobacillus Bifidobacterium genus in the amount of 107 CFU/ml, which corresponds to the number indicated on 
the label of products. It is identified that the survival rate of test-strains cultured with pasteurized products does not exceed 10%. 
The cell concentration of target-microorganisms was reduced by 20-45% after the interaction with living probiotic bacteria. Thus, 
the yogurt Activia has the most antagonistic activity. 
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1. Introduction 
 
Environmental deterioration, stress, eating disorders (deficiencies of plant food, vitamins, synthetic substitutes) 
led to the development and practical implementation of the concept "probiotics and food products", or foodstuffs, 
developed in the last decade of the 20th century1. The term "probiotic" refers to a product based on intestinal 
commensals which are capable of implementing a biological control in the body and have regulatory and trigger 
properties1. 
Probiotics contain live lactic-acid bacteria belonging to the most typical representatives of the normal human 
intestinal microflora (lactobacilli, bifidobacteria, colibacteria)1-11. The list of probiotic microorganisms that may 
have positive health effects is quite extensive. All variety of probiotics, depending on the functional activity, are 
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divided into four generations1-2. An analysis of the literature1-47 showed that probiotics are used for correcting 
microecological disturbances of acute and chronic diseases such as dysfunction of the gastrointestinal tract4,6,26-29, 
diseases of the cardiovascular system38,43, and metabolic disorders after antibiotic, hormone and radiation therapy. 
Probiotics are also used in surgical practice in the preoperative and postoperative period, in gynecology for 
correcting dysbiotic states of the genital tract of women1,22,28, and in cases of dysimmunity8,16, allergic diseases and 
others1,31,38. Biological potential of probiotics is primarily due to an antagonistic activity, associated with the 
synthesis of lactic and acetic acids, as well as other numerous metabolic effects, including the synthesis of vitamins 
B, K and of short-chain fatty acids (SCFA), the dietary carcinogen inactivation, the bacterial fermentation of certain 
drugs, the synthesis of signal molecules, etc.8,31,43,44. Besides the above areas of a prophylactic application of 
probiotics, currently, some prerequisites were outlined for the expansion of their use, and, in particular, for the 
reduction of blood serum cholesterol45, prevention of saprodontia46 and nosocomial diarrhea47,48,49 etc. 
Today in Russia there are about 100 registered probiotics, regulating a balance of intestinal microflora, that are 
based on living organisms or their metabolic products7,30,38,43,44. Every year, new food additives and food products 
containing probiotic microorganisms are produced on the market1,9,16,44. However, the claim on the label stating that 
the product contains living micro-organisms in a large amount is not always true. Furthermore, the very presence of 
probiotic microorganisms in the products is not evident of their functional efficiency; thus, the ability of such 
products to inhibit "harmful" bacteria cannot simply be declared1,2.  
In this regard, the purpose of the work was to conduct microbiological quality control of probiotic foods – 
namely, to establish belongings of microorganisms to the Lactobacillus and Bifidobacterium genus, and to 
determine the quantitative content of living probiotic microorganisms and the antagonistic activity of probiotic 
cultures. 
 
2. Materials and Methods 
 
For this research, the following functional foodstuffs containing probiotic cultures were examined: the drinkable 
yogurt "Activia" (company Dannon, manufactured in Russia, settlement Lyuuchany) containing Bifidobacterium 
actiregularis; the drinkable yogurt "Dannon" (company Dannon, manufactured in Russia, settlement Lyuuchany) 
containing Lactobacillus casei; the drinkable yogurt "Imunele" (company Wimm -Bill- Dan, manufactured in 
Russia, city Moscow) containing Lactobacillus casei and Lactobacillus rhamnosus; and the children's porridge 
"Pomogayka" (company Nestle, manufactured in Russia, city Moscow) containing Bifidobacterium sp. These 
probiotic products were stored at a temperature not exceeding 40C, following all conditions of proper storage. 
To study the antagonistic activity as targets, the following microorganism strains were examined: 
Staphylococcus aureus 668, Proteus vulgaris 588, Salmonella typhimurium 59-60 (representative office 
"Medgamal" of the Scientific Research Institute of Epidimiology and Microbiology (SRIEM) named after N. F. 
Gamaleya, Russian Academy of Medical Sciences (RAMS), Moscow). 
To isolate, cultivate and examine the properties of lactobacilli and bifidobacteria, the media produced by the firm 
Himedia (India) were used. They are presented in Table 1. 
 
Table 1. Culture media. 
 
Name of medium Abbreviation Purpose 
Lactobacillus  MRS Broth MRS Isolation of lactobacilli 
Lactobacillus MRS Agar LBA Identification and quantitative account of lactobacilli 
Bifidobacterium Broth ВВВ Isolation of bifidobacteria 
Bifidobacterium Agar ВВА Identification and quantitative account of bifidobacteria 
Nutrient Broth NB Determination of antibiotic activity 
Nutrient Agar NА Cultivation of strains of test microorganisms 
 
To isolate the bacteria lactobacilli and bifidobacteria from probiotic food products, the product culture method of 
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selective media was used. Inoculations were incubated for 48 hours at a temperature of 370C in microaerophilic 
conditions in packages «Gaspak» produced by the company "Himedia" (India). 
The categorization of selected isolates into the Lactobacillus and Bifidobacterium genus was conducted on a 
cultural-morphological basis (growth characteristics and cell morphology) and physiological and biochemical 
characteristics (formation of catalase enzyme). Cell morphology (shape, location, mobility, and presence or absence 
of spores belonging to the Gram-stain) was studied using a laboratory microscope "Biolam" M (produced by the 
open joint-stock company (OJSC) "LOMO", Russia) according to generally accepted practice in microbiological 
techniques. 
The determination of total lactic-acid bacteria in functional foodstuffs was performed by the method of Koch. 
The inoculation on solid media was done in dilutions 1:105, 1:106 in duplicate. 
To study the antagonistic action of probiotic products on opportunistic-pathogenic bacteria, the method of 
product co-culture with test-strains was used. The proportions of ingredients were as follows: 0.1 g of a product 
suspension and 1.0 ml of a test-culture containing 108 cells in 1 ml. The cultivation was carried out for 2 hours in a 
thermostatic shaker at a temperature of 370C with a rotation speed of 220 rpm (thermostat-shaker WiseCube, 
Germany). The inhibitory effect of the product was evaluated by the survival rate of a test-microorganism at a co-
cultivation in the medium, containing a probiotic product. 
 
3.  Results and Discussion 
 
The isolation and identification of bacteria in probiotic products was carried out on selective media with a 
subsequent determination of cultural and morphological properties. In the study of morphological characteristics in 
products with lactobacilli (Imunele, Dannon), small cream-colored colonies with a smooth edge and convex shape 
were found. Being gram-positive and catalyst-negative, they have a fine-grained structure with the characteristic 
odor of sour milk. In a solid medium with probiotic products Activia, Pomogayka, containing bifidobacteria, gram-
positive asporogenous (nonspore-forming) colis with a flat or slightly curved shape were found. The ends of the 
colis of the majority of bifidobacteria are forked but can also be refined or thickened in the form of spherical 
bubbles. The length varies from 0.5-1.3 – 1.5-8.0 μm. In the semi-solid medium, isolated colonies in the form of 
studs or sticks are formed. On the basis of culture-morphological (growth characteristics and cell morphology) and 
physiological and biochemical characteristics it is concluded that the isolated cultures belong to the Lactobacillus 
and Bifidobacterium genus.  
According to the modern requirements, probiotic bacteria in these products must be alive and in a large number 
(at least 106-107 CFU in 1 g of a product). These requirements relate to the fact that most of these bacteria are killed 
in the stomach and duodenum5. Although probiotics, included in the ferment structure, are specifically tested for 
resistance to gastric acid and bile, only 5-10% of living bacteria reaches the large intestin3. However, such products 
do not always contain the number of bacterial cells which is indicated on the label4. In this regard, the quantitative 
content of beneficial bacteria was examined in probiotic products. The inoculation was done within two days of 
purchasing the product. Results determining the number of living cells in the tested products are presented in Table. 
2. 
 
Table 2. Contents of lactobacilli and bifidobacteria (CFU/g) in functional foodstuffs. 
Product 
The number of living probiotic bacteria in 1g of the 
product 
Stated number Actual number 
Pomogayka 106 2х107 
Imunele  107 5х107 
Activia 107 3х107 
Dannon 107 3х107 
 
It was determined that the content of probiotic bacteria in the studied products fully meet their quantity indicated 
on the label of products. However, the presence of living probiotic bacteria in food does not guarantee their 
efficiency, the majority of which is intermicrobe antagonism. 
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Antagonistic properties of lactobacilli are the basis for the creation of probiotics, which are a physiological 
means of suppressing excessive reproduction of opportunistic-pathogenic microorganisms, as well as the correction 
of the number of individual components of the resident microflora at dysbacterioses. The formation of lactic and 
acetic acid, lysozyme, hydrogen peroxide, and bacteriocins inhibit the generation of other bacteria, including enteric 
pathogens and opportunistic-pathogenic bacteria in the process of metabolism of lactobacilli and bifidobacteria. As 
target-microorganisms, Staphylococcus aureus, Salmonella typhimurium (food poisoning germs), and Proteus 
vulgaris (aerobic rotting pathogen) were selected. The presence of these bacteria in food indicates that they are 
unsafe to eat; the realization of such products is prohibited. 
To determine antagonistic abilities, the method of co-cultivation of the above three test-cultures in culture fluid 
MRS-5 with selected products was used. The inhibitory effect of probiotic products is determined by the level of 
survival rate (%) of test-strain cells (Table 3). 
 
Table 3. The antagonistic activity of probiotic products and their probiotic components co-cultured with the test-organisms. 
 
Product Variant of experiment 
Survival rate of test-strain cells, % 
Staphylococcus aureus 
668 
Proteus 
vulgaris 
588 
Salmonella 
typhimurium 59-60 
Activia Raw product 63 70 58 Pasteurized product 90 87 88 
Imunele Raw product 82 85 80 Pasteurized product 96 92 96 
 
As can be seen from the data, after pasteurization, the product has almost no inhibitory effect on the growth of 
the test-strains. The survival rate of test-strains when cultured with pasteurized products is no more than 10% 
different from the control. A negative effect was only evident in the original product which contained living 
cultures. The cell concentration of target-microorganisms after the interaction with living probiotic bacteria was 
reduced by 20-45%. The yogurt Activia has the most antagonistic activity, which is composed of living 
bifidobacteria. In this case, test-microbe survival is 63% for S.aureus, 70% for P.vulgaris and 58% for 
S.typhimurium. 
 
4.  Conclusions 
 
During the microbiological control of functional foodstuffs, it was determined that drinkable yogurts such as 
Activia, Imunele, and Dannon contain living lactobacilli and bifidobacteria in the amount of 107 CFU/ml. In the 
children's porridge Pomogayka, bifidobacteria are found at a titre of 106 CFU/g. The content of probiotic bacteria in 
these products fully meet their quantity indicated on the product label. The identification by culture-morphological, 
physiological and biochemical characteristics supports that selected isolates belong to the Lactobacillus 
Bifidobacterium genus. It is identified that the survival rate of test-strains cultured with pasteurized products is not 
more than 10% different from the control ones. Most antagonistic activity has a probiotic product Activia. 
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